Kineta, Inc. (KA) Research

Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.

Market snapshot

Symbol
KA
Price
$0.57
Day change
-30.77%
Market cap
$7.0M
P/E ratio
-2.24x
52-week range
0.3339-5.39
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Biora Therapeutics, Inc. (BIOR)
  • COSCIENS Biopharma Inc. (CSCI)
  • Entero Therapeutics, Inc. (ENTO)
  • ESSA Pharma Inc. (EPIX)
  • Fresh Tracks Therapeutics, Inc. (FRTX)
  • Omega Therapeutics, Inc. (OMGA)
  • Tricida, Inc. (TCDA)
  • Turnstone Biologics Corp. (TSBX)

Recent insider activity

  • Peters Richard — A-Award (12500 shares) on 2024-09-04
  • Iadonato Shawn — A-Award (12500 shares) on 2024-09-04
  • Foote Marion R — A-Award (12500 shares) on 2024-09-04
  • Dylla Scott J. — A-Award (12500 shares) on 2024-09-04
  • Drapkin Kimberlee C — A-Award (12500 shares) on 2024-09-04

Open Kineta, Inc. (KA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.